Categories: News

Sema4 to Participate at Two Upcoming Investor Conferences in February

STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences:

  • BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
    Fireside chat and 1x1s on Thursday, February 17th, 2022 at 10:00 a.m. ET
  • SVB Leerink 11th Annual Global Healthcare Conference
    Formal presentation and 1x1s on Friday, February 18th, 2022 at 2:20 p.m. ET

A live and archived webcast of the SVB Leerink presentation will be available on the “Events” section of the Sema4 investor relations website at https://ir.sema4.com/.

About Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

Investor Relations Contact:
Joel Kaufman
Sema4
investors@sema4.com

Media Contact:
Radley Moss
Sema4
radley.moss@sema4.com

Staff

Recent Posts

For Pride Month, Mental Health Professionals Offer Parenting Help

Parenting is a hard job under the best of circumstances. It can be especially confusing…

2 hours ago

Curiteva Announces the Beginning of the Commercial Launch of the Inspire(R) Posterior Interbody Solutions

HUNTSVILLE, AL / ACCESSWIRE / June 19, 2024 / Curiteva, Inc., a leading technology and…

2 hours ago

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

2 hours ago

Sharecare announces inducement grants under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, June 19, 2024 (GLOBE NEWSWIRE) -- Sharecare (NASDAQ: SHCR), the digital health company that…

2 hours ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people…

2 hours ago

Calibre Scientific Acquires DCS, a German Provider of Antibodies, Reagents and Equipment Used in Immunohistochemistry

LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the…

2 hours ago